Indeed, the treatment with RU486 + VMF + UMI-77 (UMI77 is a selective small-molecule inhibitor of Mcl-1 [177]) or RU486 + VMF + WEHI77 (WEHI77 is Bcl-xL-selective BH3 mimetic [178]) almost induced a complete regression of advanced BRAFV600E-mutated melanoma metastases depending on which of these Bcl-2-related proteins was preferentially overexpressed in the different human BRAFV600E melanomas tested [109]. The gene discussed is BCL2L1; the disease is melanoma.